KOSPI · 326030
SK Biopharm
Market cap₩5.90T
PER14.73×
PBR5.78×
Foreign ownership11.71%
Avg. analyst target₩144,688
Pension summary
as of Oct 19streak2-day net sell
5D-₩710M
20D-₩4.1B
60D-₩9.2B
Foreign 20D-₩24.1B
Inst. 20D+₩4.7B
Pension daily net buy
-Cumulative net buying by investor
-선택 기간의 net buy Total · ₩100M
| Date | Close | Pension funds | Foreign | Institutions | Retail |
|---|---|---|---|---|---|
| 10/19 | 75,700 | -₩290M | +₩640M | +₩560M | -₩1.1B |
| 10/16 | 73,400 | -₩60M | +₩1.8B | +₩1.9B | -₩3.3B |
| 10/15 | 68,800 | +₩160M | -₩1.1B | +₩2.6B | -₩1.5B |
| 10/14 | 70,000 | -₩380M | +₩400M | -₩420M | +₩170M |
| 10/13 | 70,100 | -₩140M | +₩190M | +₩1.0B | -₩1.3B |
| 10/12 | 70,800 | -₩90M | -₩80M | +₩780M | -₩690M |
| 10/8 | 72,700 | -₩260M | -₩2.5B | -₩2.3B | +₩4.6B |
| 10/7 | 75,300 | -₩340M | -₩1.7B | -₩380M | +₩2.1B |
| 10/6 | 77,300 | +₩340M | -₩2.8B | +₩600M | +₩2.1B |
| 10/2 | 76,400 | -₩190M | -₩2.0B | +₩130M | +₩1.8B |
Discussion
Google-verified members · return since posting- Loading
세력 매집
last 60 trading days · Oct 19Foreign 60D−₩35.8B
Pension funds 60D−₩9.2B
세력 Avg. cost82,486
vs. cost Close-8.5%
Foreign+Pension funds Total 시총의 -0.8%, 60D price 폭 28%·Chg -1.7%. 세력 Avg. cost net buy한 날의 Avg 매수단가로 낸 est.치예요.
세력 매집 구간 All →Financial score
#11 of KOSPI 50079.2/100
- Value15
- Quality20
- Growth18
- Financials13
- Risk13.2
소외촉매 대기
이익이 실제로 늘어 숫자는 믿을 만하나, 경쟁약 위험은 점수에 안 잡혀 있고 TargetPremium +90%도 Broker price targets 낙관적인 영향이라 참고만 할 것.
All stock scores →ETF
ETFs holding it in their top 10 · recent changes10/08 이후 큰 ETF 변화는 없어요
All ETF index changes →Recent filings
DART- Loading
Broker price targets
Recent 1YAvg150,000
High165,000
Low120,000
| Broker | Rating | Target | vs prior | Date |
|---|---|---|---|---|
| Hana Securities | Buy | 160,000 | Unch. | 26.10.19 |
| iM Securities정OO | Buy | 130,000 | Unch. | 26.09.15 |
| DS Securities | Buy | 155,000 | ▲7% | 26.08.27 |
| SK Securities이OO | Buy | 160,000 | Unch. | 26.08.27 |
| Mirae Asset Securities | Buy | 160,000 | ▲7% | 26.08.27 |
| Kyobo Securities | Buy | 150,000 | Unch. | 26.08.06 |
| Kiwoom Securities | Buy | 120,000 | ▼14% | 26.08.06 |
| IBK Securities정OO | Buy | 165,000 | Unch. | 26.05.08 |
Recent reports
- 실적은 양호할 것, 오파칼림 업데이트 중요(3Q26 Pre)Hana Securities · 10/19
- 임상 보류에 대한 과도한 우려iM Securities · 09/15
- 부분 보류는 제한적, 검증은 이제부터Kiwoom Securities · 09/14
- 1200 people 이상 사례 없었음, 문제 빠르게 해소될 것Hana Securities · 09/14
- 드디어 등장한 2nd 파이프라인, 오파칼림DS Securities · 08/27
Latest report per broker in the past year · Source: Naver Securities Research, Hankyung Consensus · Analyst names masked
Same sector
SK Biopharm summary
SK Biopharm (326030). Pension funds: -₩4.1B over the last 20 trading days; 2-day net selling streak. Market cap ₩5.90T, PER 14.73×, PBR 5.78×. Avg. analyst target ₩144,688. Pension flows are based on Korea Exchange investor statistics, for reference only.